CODX News

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

CODX

(NASDAQ:CODX) SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of...

September 11, 2025Diagnostics
Read more →

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

CODX

SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th...

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

CODX

SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025...

August 14, 2025Earnings
Read more →

Co-Diagnostics Q1 EPS $(0.24) Beats $(0.33) Estimate, Sales $50.28K Miss $375.00K Estimate

CODX

May 8, 2025
Read more →

D. Boral Capital Initiates Coverage On Co-Diagnostics with Buy Rating, Announces Price Target of $10

CODX

April 28, 2025
Read more →

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $1

CODX

March 28, 2025
Read more →

Co-Diagnostics FY 2024 GAAP EPS $(1.24) Misses $(1.22) Estimate, Sales $3.900M Miss $4.141M Estimate

CODX

March 27, 2025
Read more →

Uncovering Potential: Co-Diagnostics's Earnings Preview

CODX

March 26, 2025
Read more →

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

CODX

Co-Diagnostics plans to submit an enhanced COVID-19 test for FDA clearance, addressing stability concerns and integrating platform advancements.

February 24, 2025
Read more →

Co-Diagnostics Withdraws 510(k) Application For Co-Dx PCR COVID-19 Test After FDA Dialogue, Plans Enhanced Version Submission

CODX

February 21, 2025
Read more →